Please login to the form below

Not currently logged in
Email:
Password:

niraparib

This page shows the latest niraparib news and features for those working in and with pharma, biotech and healthcare.

AZ and MSD surpass rivals with updated Lynparza data

AZ and MSD surpass rivals with updated Lynparza data

Rival Tesaro is also expecting phase III results in the same setting for its PARP inhibitor Zejula (niraparib), but much like Lynparza, that data won’t be available until next year.

Latest news

More from news
Approximately 3 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    Licensing one indication for a new product is unusual not least of all because of potential pricing issues if niraparib is launched by different companies at different prices. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics